Drug

Vinorelbine (Navelbine)

A weekly chemotherapy drug for lung and breast cancer

Updated: 28 October 20261 min read3 references
Generic name
Vinorelbine
Brand names
Navelbine
Drug class
Vinca alkaloid (microtubule inhibitor)
Route
Intravenous injection
Show content for:

Key points

  • Vinorelbine is injected into a vein once a week, alone or with cisplatin [1].
  • Given with cisplatin after surgery for lung cancer, it kept more patients alive [2, 3].
  • If it leaks out of the vein it damages the skin; report any burning at the injection site straight away [1].

What is this drug and how does it work?

For patients

Vinorelbine stops the cell from building the fibres it needs to divide, and so stops cancer cells from dividing [1].

For physiciansSpecialist notes
For physicians

A semi-synthetic vinca alkaloid; inhibits tubulin polymerisation and arrests mitosis [1].

Which cancers is it used for?

For patients
What is this drug for?
  • Non-small cell lung cancer: after surgery with cisplatin, or in advanced disease [1, 2, 3]
  • Advanced breast cancer (a common use)
For physiciansApproved uses and evidence
For physicians
Approved uses and evidence
DiseaseUseKey evidence
Lung cancer after surgery (IB to IIIA)With cisplatinJBR.10 and ANITA: longer overall survival than observation [2, 3]
Advanced lung cancerWith cisplatin or alone [1]—

How it is given and dose

Show detailsHide

Once a week, a short injection (6 to 10 minutes) into a vein, followed by flushing the vein with a drip [1].

For physiciansStandard dose (FDA label), 1 regimen
For physicians

Standard dose (FDA label)

Vinorelbine

Non-small cell lung cancerCycle length: Weekly

Non-small cell lung cancer

DrugDoseRouteSchedule
With cisplatin 100
Vinorelbine25 mg/m²IV over 6 to 10 minutesDays 1, 8, 15 and 22 every 28 days
Single agent
Vinorelbine30 mg/m²IVWeekly
Cycle length
Weekly
Duration
According to regimen

With cisplatin 100 mg/m² on day 1 every 28 days. Reduce the dose with neutropenia or raised bilirubin. Vesicant: IV only, and avoid extravasation [1].

Doses follow the trial protocol, guideline or official drug label (source given in the notes of each regimen). Before prescribing, check blood counts, renal and hepatic function, drug interactions and the patient’s condition, and adjust the dose according to the drug label.

Side effects

For patients

The most common side effects: low white blood cells, tiredness, nausea, constipation, mild hair loss, and pain or inflammation of the vein at the injection site [1].

For physiciansSpecialist notes
For physicians

Neutropenia (dose-limiting; boxed warning), anaemia, raised liver enzymes, nausea, constipation, asthenia, injection-site phlebitis [1].

Serious side effects

For patients

Serious side effects: infection with low white blood cells, severe constipation and bowel blockage, numbness in the hands and feet, lung damage, and skin damage if the drug leaks out of the vein [1].

For physiciansSpecialist notes
For physicians
  • Myelosuppression: blood count before each dose [1].
  • Severe constipation and ileus: preventive laxatives [1].
  • Neuropathy, pulmonary toxicity, hepatotoxicity [1].
  • Vesicant; for extravasation, follow the extravasation lesson [1].

When should I call my doctor?

  • A temperature of 38 °C or higher
  • Constipation for more than 3 days, or abdominal pain
  • Burning, swelling or redness at the injection site
  • New shortness of breath

Interactions, pregnancy and precautions

  • Constipation: enough fluids and a laxative as your doctor advises from the day of the injection [1].
  • Other medicines: antifungals and clarithromycin raise the amount of the drug [1].
  • Pregnancy: this drug may harm an unborn baby; use effective contraception during treatment and tell your doctor straight away if you become pregnant. Do not breastfeed during treatment [1].
For patients

Frequently asked questions

Does vinorelbine make your hair fall out?

Hair loss is usually mild [1].

Related cancer types

References

3 references
Show all referencesClose the reference list

Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.

  1. 1
    VINORELBINE — Prescribing InformationActavis Pharma, Inc · FDA label · 2026
    Source Back to text: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
  2. 2
    Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancerWinton T, Livingston R, Johnson D, et al · N Engl J Med · 2005;352:2589-97
    DOIPubMed Back to text: 1 2 3
  3. 3
    Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trialDouillard JY, Rosell R, De Lena M, et al · Lancet Oncol · 2006;7:719-27
    DOIPubMed Back to text: 1 2 3

This page is based on reputable scientific sources and was last updated on 28 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.